
CymaBay Therapeutics CBAY
Annual report 2023
added 02-28-2024
CymaBay Therapeutics Depreciation & Amortization 2011-2026 | CBAY
Annual Depreciation & Amortization CymaBay Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 681 K | 625 K | 669 K | 632 K | 572 K | 105 K | 35 K | 29 K | 22 K | 18 K | 55 K | 119 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 681 K | 18 K | 297 K |
Quarterly Depreciation & Amortization CymaBay Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 199 K | - | 525 K | 343 K | 169 K | - | 515 K | 339 K | 164 K | - | 468 K | 309 K | 153 K | - | 422 K | 278 K | 138 K | - | 39 K | 25 K | 12 K | - | 26 K | 18 K | 9 K | - | 21 K | 11 K | 5 K | - | 17 K | 11 K | 6 K | - | 13 K | 8 K | 3 K | - | 50 K | 41 K | 26 K | - | 91 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 525 K | 3 K | 139 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Amgen
AMGN
|
5.17 B | $ 350.12 | 2.98 % | $ 188 B | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Amneal Pharmaceuticals
AMRX
|
57.3 M | $ 12.68 | 2.92 % | $ 3.97 B | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 24.48 | 5.18 % | $ 3.11 B | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.5 | 9.93 % | $ 399 M | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.68 | 4.28 % | $ 16.8 M | ||
|
Avid Bioservices
CDMO
|
11.1 M | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
154 K | - | - | $ 1.41 B | ||
|
Cabaletta Bio
CABA
|
1.65 M | $ 3.05 | -0.65 % | $ 306 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 K | $ 3.1 | 2.31 % | $ 6.75 B | ||
|
Cerus Corporation
CERS
|
1.43 M | $ 1.92 | 4.08 % | $ 366 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Concert Pharmaceuticals
CNCE
|
1.48 M | - | - | $ 401 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
CTI BioPharma Corp.
CTIC
|
1.95 M | - | - | $ 1.2 B | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
5 K | - | -4.36 % | $ 27 M | ||
|
Cellectar Biosciences
CLRB
|
214 K | $ 2.81 | 2.18 % | $ 7.33 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
2.1 M | - | - | $ 2.18 B | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Dynavax Technologies Corporation
DVAX
|
4.63 M | - | - | $ 2.02 B | ||
|
Cyclerion Therapeutics
CYCN
|
65 K | $ 3.43 | -1.43 % | $ 8.64 M |